Feb 11, 1999 CE
Genmab Founded
Genmab is founded in Copenhagen, Denmark, by Glaxo Wellcome (now GSK), and other investors, with initial funding of DKK 450 million. #biotech #founding
Chronological Storyline (32 Milestones)
Jun 29, 2000 CE
IPO on Nasdaq Copenhagen
Genmab goes public on the Copenhagen Stock Exchange (Nasdaq Copenhagen), raising DKK 825 million. #IPO #biotech
May 1, 2001 CE
First Collaboration with Medarex
Genmab enters a collaboration agreement with Medarex to develop antibody therapeutics using Medarex's UltiMAb technology. #biotech #partnership
Jan 1, 2002 CE
Extended Collaboration with Medarex
Genmab expands its collaboration with Medarex, gaining access to additional antibody discovery tools. #biotech #partnership
Mar 1, 2003 CE
Initiation of Phase I for HuMax-CD4
Genmab initiates its first Phase I clinical trial for HuMax-CD4, a potential treatment for T-cell lymphoma. #biotech #clinicaltrials
Sep 1, 2004 CE
Collaboration with GSK on Ofatumumab
Genmab enters a global licensing agreement with GlaxoSmithKline (GSK) to develop and commercialize ofatumumab, a CD20-targeting antibody. #biotech #partnership
Dec 1, 2006 CE
Positive Phase III Results for Ofatumumab in CLL
Genmab and GSK announce positive Phase III trial results for ofatumumab in chronic lymphocytic leukemia (CLL). #biotech #clinicaltrials
Jun 1, 2007 CE
GSK Exercises Option for Ofatumumab
GlaxoSmithKline exercises its option to license ofatumumab, triggering a milestone payment to Genmab. #biotech #partnership
Apr 1, 2008 CE
New Headquarters in Copenhagen
Genmab moves to a new headquarters facility in Copenhagen, Denmark, to accommodate growth. #biotech #Denmark
Oct 26, 2009 CE
FDA Approval of Arzerra (Ofatumumab)
The U.S. FDA approves Arzerra (ofatumumab) for the treatment of chronic lymphocytic leukemia (CLL) in patients who are refractory to fludarabine and alemtuzumab. #FDA #biotech
Aug 1, 2010 CE
Collaboration with Janssen on Daratumumab
Genmab enters into a global licensing agreement with Janssen Biotech (Johnson & Johnson) to develop and commercialize daratumumab, a CD38-targeting antibody. #biotech #partnership
Mar 1, 2011 CE
Phase I/II Trials for Daratumumab Begin
Genmab and Janssen initiate Phase I/II clinical trials for daratumumab in multiple myeloma. #biotech #clinicaltrials
Dec 1, 2012 CE
Daratumumab Granted Breakthrough Therapy Designation
The U.S. FDA grants Breakthrough Therapy designation for daratumumab in multiple myeloma, accelerating its development. #FDA #biotech
Sep 1, 2013 CE
Genmab Establishes US Subsidiary
Genmab establishes a wholly-owned US subsidiary in Princeton, New Jersey, to support clinical development and commercial activities. #biotech #expansion
Dec 1, 2014 CE
Positive Phase III Results for Daratumumab
Genmab and Janssen announce positive Phase III trial results for daratumumab in relapsed/refractory multiple myeloma. #biotech #clinicaltrials
Nov 16, 2015 CE
FDA Approval of Darzalex (Daratumumab)
The U.S. FDA approves Darzalex (daratumumab) for the treatment of multiple myeloma in patients who have received at least three prior lines of therapy. #FDA #biotech
May 20, 2016 CE
European Approval of Darzalex
The European Commission grants marketing authorization for Darzalex as a monotherapy for multiple myeloma. #EU #biotech
Jul 1, 2016 CE
First Royalty Revenue from Darzalex
Genmab reports its first royalty revenue from Darzalex sales by Janssen, marking a major financial milestone. #biotech #revenue
Feb 1, 2017 CE
Genmab Achieves Profitability
Genmab reports its first full-year net profit, driven by royalty income from Darzalex. #biotech #financial
Mar 1, 2018 CE
Launch of HexaBody Technology Platform
Genmab introduces the HexaBody technology platform for enhanced antibody effector function. #biotech #technology
May 2, 2019 CE
FDA Approval of Darzalex Faspro (Subcutaneous)
The U.S. FDA approves Darzalex Faspro, a subcutaneous formulation of daratumumab, developed with Janssen. #FDA #biotech
Apr 1, 2020 CE
Genmab Expands Pipeline with Epcoritamab
Genmab announces promising Phase I/II data for epcoritamab, a CD3xCD20 bispecific antibody, in B-cell non-Hodgkin lymphoma. #biotech #clinicaltrials
Jun 1, 2021 CE
Genmab Reports Positive Phase II Results for Epcoritamab
Genmab and collaborator AbbVie announce positive Phase II results for epcoritamab in diffuse large B-cell lymphoma (DLBCL). #biotech #clinicaltrials
Jan 1, 2022 CE
Genmab Enters Collaboration with BioNTech
Genmab announces a strategic collaboration with BioNTech to develop bispecific antibodies for cancer. #biotech #partnership
May 1, 2022 CE
Genmab to Acquire ProfoundBio
Genmab announces agreement to acquire ProfoundBio, gaining access to its ADC platform and pipeline. #biotech #acquisition
Aug 1, 2022 CE
Completion of ProfoundBio Acquisition
Genmab completes the acquisition of ProfoundBio, expanding its antibody-drug conjugate capabilities. #biotech #acquisition
Jan 31, 2023 CE
Epcoritamab (Tepkinly) FDA Approval for DLBCL
The U.S. FDA approves Tepkinly (epcoritamab) for the treatment of relapsed/refractory diffuse large B-cell lymphoma. #FDA #biotech
May 1, 2023 CE
Genmab Expands Manufacturing Facility in Denmark
Genmab announces expansion of its manufacturing facility in Hillerød, Denmark, to increase production capacity. #biotech #manufacturing
Sep 1, 2023 CE
Genmab Enters Research Collaboration with Poseida Therapeutics
Genmab partners with Poseida Therapeutics to develop novel CAR-T therapies for multiple myeloma. #biotech #partnership
Mar 1, 2024 CE
Genmab Reports Record Revenue for 2023
Genmab announces annual revenue of DKK 16.5 billion for 2023, driven by Darzalex royalties and Tepkinly sales. #biotech #financial
Jun 1, 2024 CE
Genmab Receives European Approval for Tepkinly
The European Commission approves Tepkinly (epcoritamab) for DLBCL, expanding its geographic reach. #EU #biotech
Oct 1, 2024 CE
Genmab Initiates Phase III Trials for HexaBody-DR5/DR5
Genmab begins Phase III trials for its bispecific antibody HexaBody-DR5/DR5 targeting solid tumors. #biotech #clinicaltrials